Tramadol, buy tramadol, antibiotics, Weight Loss drugs, weight loss herbs, weight loss herbal formula, weight loss, hair loss, hair growth, baldness, Rx Online, pharmaceuticals, DHEA, Lutein, Prescription, Prescription drug, prescription medications, laxative.

DreamPharm Products:

Lutein-20||Herbs for headache, fever, and migraine || Milk thistle||Saw palmetto|| Triple B Super Vision||Garlic, Ginger, and Grapeseed Extract|| Ginseng and Ginkgo||Hair Million|| DHEA||Coenzyme Q10|| Sleep Aid herbal formula - natural sleep aid||Herbal Breath - herbs for bad breath problems.|| Weight loss herbal formula||Ginkgo biloba|| Colon cleansing, Laxative for constipation relief, laxative, and colon cleansing||ViaVita, Lecithin for healthy liver

Interferon research abs 1 || Hemoglobin research abs || Stem cell research abs || Nucleic acid research abs || Herpes research abs || Bronchitis research abs || Schizophrenia research abs || Tuberculosis research abs || Pneumonia research abs || Constipation research abs || Laxative research abs

J Am Med Dir Assoc. 2003 Jul-Aug;4(4):183-8.
Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia.

Martin H, Slyk MP, Deymann S, Cornacchione MJ.

Creative Care Consulting, Clark, New Jersey 07066, USA.

OBJECTIVE: To assess the adverse events associated with the appropriate use of oral risperidone and oral olanzapine in long-term care patients with behavioral and psychotic disturbances associated with dementia. DESIGN: Observational analysis. SETTING: Analysis was performed at five consulting pharmacist sites across the United States. Participants were recruited at 89 skilled nursing facilities by consultant pharmacists who provided services at each site. PATIENTS: A total of 730 men and women with dementia who had been residents of a skilled nursing facility for at least 90 days were included in the study. Alzheimer's disease was the primary diagnosis in 47% of patients. INTERVENTION: Patients were treated with risperidone < or =2 mg/day or olanzapine < or =10 mg/day for at least 90 days. MEASUREMENTS: Targets for antipsychotic use included nonaggressive symptoms of psychosis and verbally and physically aggressive behaviors. The effects of risperidone and olanzapine were determined from progress notes, psychotropic monitoring forms, and physicians' order forms after 91 days of treatment. Adverse events of particular significance in the elderly population, including agitation/anxiety, laxative use, dry eyes, and falls, were collected from audited medical records. The evaluation period extended from 3 months before to 3 months after initiation of treatment with risperidone or olanzapine. RESULTS: There were 474 patients in the risperidone group and 256 patients in the olanzapine group. Mean dosages of risperidone at Days 1 and 91 (0.7 +/- 0.3 mg/day and 1.0 +/- 0.5 mg/day, respectively) and olanzapine (3.3 +/- 1.4 mg/day and 4.7 +/- 2.1 mg/day, respectively) were at least 50% lower than the maximum dosages recommended by the Center for Medicare and Medicaid Services for elderly patients with psychosis or behavioral symptoms of dementia. The need for eye lubrication was minimal in both groups and did not differ significantly between them. Anxiolytic use decreased in the risperidone group and remained constant in the olanzapine group, with no significant difference between groups. In the olanzapine and risperidone groups, the number of patients with orders for laxatives increased 10.2% and 1.8%, respectively (P = 0.003), the mean number of days of laxative administration increased 19.1% and 4.3%, respectively (P < 0.001), and the mean number of doses of laxative administered increased 14.2% and 4.1%, respectively (P = 0.001). Among patients qualifying for analysis, falls were recorded for 17.9% of patients receiving olanzapine and 6.9% receiving risperidone (P = 0.001). CONCLUSION: Among long-term care residents with dementia who received low doses of risperidone or olanzapine, the incidence of adverse events was low. When considering adverse events of particular concern in the elderly, specifically falls and laxative use, risperidone may be preferred over olanzapine in this population.

online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12837138&dopt=Abstract

Gastrointest Endosc. 2003 Jul;58(1):30-5.
An open-label trial of L-glucose as a colon-cleansing agent before colonoscopy.

Raymer GS, Hartman DE, Rowe WA, Werkman RF, Koch KL.

Pennsylvania State University, Milton S. Hershey Medical Center, Division of Gastroenterology and Hepatology, Penn State Clinical Trials Office, Hershey 17033, USA.

BACKGROUND: The high volume and poor palatability of standard colon cleansers remain obstacles to colonoscopy for many patients. Significant electrolyte disturbances and fluid balance alterations may occur with available agents. L-glucose, the stereoisomer of D-glucose, has laxative effects that make it potentially useful as a colon-cleansing agent. This study evaluated the safety and efficacy of L-glucose as a bowel cleanser before colonoscopy. METHODS: Thirty healthy individuals (age range 34-70 years) scheduled to undergo outpatient colonoscopy were given 24 g of L-glucose in 8 ounces of water to cleanse the colon. Nonblinded endoscopists rated the quality of the preparation based on established criteria. Laboratory studies were monitored before and after administration of the L-glucose and on the day after colonoscopy; adverse clinical events were also monitored. RESULTS: L-glucose administration resulted in excellent or good preparations in 80% (24/30) of the patients and fair or poor preparations in 20%. Average water consumption was 48 ounces. No adverse event occurred, and no significant laboratory test abnormalities were identified. CONCLUSIONS: Eighty percent of patients who prepared for colonoscopy by ingestion of L-glucose had good or excellent preparations. The L-glucose preparation was palatable, and its efficacy and safety appear equivalent to currently available colon-cleansing agents.

online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12838217&dopt=Abstract [PubMed - in process]

Dis Colon Rectum. 1999 Apr;42(4):457-9.
Early discharge after external anal sphincter repair.

Rosenberg J, Kehlet H.

Department of Surgical Gastroenterology, University of Copenhagen, Hvidovre Hospital, Denmark.

PURPOSE: The aim of this study was to describe an accelerated-stay program for repair of the external anal sphincter. METHODS: Twenty consecutive patients undergoing overlapping repair of the external anal sphincter were included in the study. Effect parameters were length of hospitalization and complications within 30 days after the operation. Surgery was performed during the period of March 1993 to May 1997. The accelerated-stay program included preoperative information, no premedication, a surgical procedure without colostomy, single-dose prophylactic antibiotics, paracetamol for analgesia, free oral fluid and food immediately after the operation supplemented by laxatives, and enforced mobilization. Follow-up by questionnaire was performed at a median of 14 (range, 4-52) months after the operation. RESULTS: Median hospital stay was one day. Fifteen patients were discharged the day after surgery and 5 patients stayed for 48 hours after the operation. There was no 30-day morbidity, and no patient received a colostomy in conjunction with the sphincter repair. Fourteen of 19 patients available for follow-up reported a significantly improved functional result compared with preoperative state. CONCLUSION: We have described a safe accelerated-stay program (24 to 48 hours) for overlapping repair of external anal sphincter.

online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10215044&dopt=Abstract

Hair growth is a sophisticated biological process, which is still not thoroughly understood. A multitude of therapeutic measures, including drugs, surgery, and suppelements have been made available, and used. However, due to the diversity of the problems underlying hair loss, there is no single solution for all hair loss cases. Most of chemical drugs and hair transplantation surgeries are not free from varying degrees of undesirable side effects on health.

Hair Million is an alternative solution to cope with hair loss problems. Anecdotally, it shows prositive results and improvement especially for age-related hair thinning and hair loss for a fraction of people who take it. We do not know the mechanisms of action as to how Hair Million works to help stop hair loss, and promote hair growth. We only know by anecdotal observations. There has been no clinical trials nor placebo controlled statistical analysis on the efficacy of Hair Million on hair loss and hair growth.

DreamPharm Online Healthy Supplements || Constipation relief, laxative, colon cleansing || Lutein || Progesterone Cream || Natural herbal formula for hair loss problems ||